A study to investigate the preventive effect of AG-1749 against the onset of gastric and duodenal ulcers that can be seen during long-term treatment with low dose aspirin.
Phase 3
- Conditions
- Patients that require long-term low-dose aspirin treatment to manage thrombosis, thrombus formation etc., after angina, myocardial infarction, ischemic cerebrovascular disorder, coronary artery bypass surgery or percutaneous transluminal coronary angioplasty.
- Registration Number
- JPRN-jRCT2080220484
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 812
Inclusion Criteria
1) The patient was on low-dose aspirin treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started.
2) The patient was confirmed to have a history of gastric
ulcer or duodenal ulcer (combined gastric and duodenal ulcer is also possible).
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method